Connect with us

Business

Coffeemakers are the new centerpiece? India’s growing craze for cafe-like coffee at home; lakhs splurged on aroma and style – The Times of India

Published

on

Coffeemakers are the new centerpiece? India’s growing craze for cafe-like coffee at home; lakhs splurged on aroma and style – The Times of India


Spent a fortune on a coffee machine and those exotic beans to replicate that cappuccino you loved overseas? You are not alone. For many rich Indians, the coffee machine on the kitchen counter is no longer just for making a drink, rather it has become a lifestyle statement, as more people are trying to bring the cafe experience they enjoyed overseas, right in their homes.A growing number of young, affluent consumers are spending several lakh rupees on high-end coffee machines, specialty beans and cafe-style equipment to mirror the ambience of European coffee houses. These machines, which offer far more than basic espresso or latte functions, have become objects of prestige. Brands such as Versuni, SMEG and DeLonghi are increasingly being displayed as centrepieces in kitchens and lounges, erasing the line between appliance and art.

India’s coffee craze

From only a few hunderds six years ago, now, almost 20,000 premium coffee machines are estimated to be sold locally, every year, a figure that includes direct imports by companies, ET reported. This does not includes the large number of machines that individuals bring into the country themselves while travelling abroad or order through international e-commerce platforms. With limited availability of high-end brands and models in India, parallel imports continue to rise. Ravi Saxena, founder and chief executive of Wonderchef Home Appliances, links this trend to the rapid spread of neighbourhood cafes across Indian cities. He says this has created strong interest in recreating cafe-quality coffee at home. A trained barista, Saxena sells about 1.4 lakh coffee machines a year, including premium automatic models priced between Rs 60,000 and Rs 90,000. The appetite for premium machines is also visible among frequent international travellers. Gurgaon-based hotelier Rajat Gera placed an order for an SMEG machine in December for Rs 1.3 lakh and is still waiting for it to arrive at Indian ports. “It’s a piece of art that deserves to be placed as a centrepiece in the kitchen or lounge,” he says. The overall coffee machine market in India is valued at Rs 250–300 crore and is growing at more than 15% a year. Total sales across price categories reached about 4.2–4.5 lakh units in the last calendar year, compared with roughly 1.8 lakh units in 2019. While machines priced up to Rs 15,000 continue to dominate volumes, premium models are steadily expanding their share.

Struggling for the right taste

For some buyers, the shift is rooted in dissatisfaction with cafe offerings at home. Satyendra Shukla, who runs a boutique investment firm, bought a La Carimali machine for Rs 1.5 lakh two years ago. “I had to struggle for every cup of coffee in India. No cafe could give me coffee I liked. The right texture, temperature or taste seldom came together. Now, my well travelled friends say I make the best coffee. I look after the machine and spend a lot of time sourcing the best beans. Others are prepared to absorb heavy import costs. Kolkata-based independent professional A Banerjee purchased a Philips machine priced at Rs 57,000 from Amazon UK for Rs 95,000 after accounting for shipping, customs duties and currency conversion. Gulbahar Taurani, chief executive of Versuni India, attributes rising demand to young consumers exploring different beans, flavours, aromas and brewing styles, including coffee mocktails mixed with tonic water. He said the company’s pilot launch of premium models priced up to Rs 80,000 in India has been highly successful. Versuni plans to combine its global technology with adaptations for Indian preferences. While its entire range is currently imported, Taurani has not ruled out domestic manufacturing as volumes grow. Retailers are also reporting strong traction. Coffee machines are among the fastest-moving categories in stores. Vijay Sales sells 400–500 units every month. “Coffee machines have become a lifestyle product. While most of the demand is still in the entry- to mid-segment, premium models are also selling fast. This could become a big category in the next three to four years,” said Nilesh Gupta, director, Vijay Sales. What was once a simple kitchen tool is rapidly turning into a lifestyle statement, as coffee drinkers in the country are investing not just in caffeine, but in culture and cachet at home.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Why Spotify has no button to filter out AI music

Published

on

Why Spotify has no button to filter out AI music



Music streamer Deezer allows users to filter out AI music, so why does Spotify not offer the same?



Source link

Continue Reading

Business

‘I had £20,000 stolen and had to fight a 13-month fraud reporting rule to get it back’

Published

on

‘I had £20,000 stolen and had to fight a 13-month fraud reporting rule to get it back’



Sarah has now got her money back but there are calls to reform the deadline for reporting scams to banks.



Source link

Continue Reading

Business

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Published

on

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial


Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA.

Spencer Grant | Universal Images Group | Getty Images

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration.

The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema, causing them to experience potentially life-threatening swelling attacks. Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver.

Intellia said the one-time treatment reduced attacks by 87% compared with a placebo, meeting the study’s main goal. Six months after treatment, 62% of patients were free from attacks and weren’t using other therapies, Intellia said.

The company described the safety and tolerability of the treatment as “favorable,” reporting the most common side effects were infusion-related reactions, headaches and fatigue. Analysts were closely watching safety in the trial since a patient in a separate trial of a different treatment from Intellia died. That patient developed a liver injury and ultimately died from septic shock following an ulcer, according to the company.

“When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we’ve had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you’re actually changing a gene that causes disease,” said Intellia CEO John Leonard.

The only FDA-approved Crispr-based medicine comes from Vertex Pharmaceuticals. Called Casgevy, the gene editing is done outside the body, or ex vivo. The process requires collecting a person’s blood cells, making the edits outside the body, then reinfusing them back into a patient. Intellia’s treatment, meanwhile, makes the edits inside the body, or in vivo.

Intellia said it has started a rolling application with the FDA and plans to complete the filing in the second half of this year. The company expects to launch the treatment in the U.S. in the first half of next year, if it’s approved.

If approved, Intellia’s treatment, lonvoguran ziclumeran, will compete with about a dozen other chronic drugs for HAE. Despite the allure of a one-time treatment, genetic medicines haven’t always been a commercial successes. BioMarin withdrew its gene therapy for Hemophilia A because of weak sales, for example.

Leonard said there are important differences between the two, like the fact that BioMarin’s therapy faced questions about how long the effects would last. In contrast, he said Intellia hasn’t seen a single case in almost six years where the effects diminished over time.

Despite the results, he’s reluctant to call Intellia’s treatment a functional cure.

“I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it’s permanent,” Leonard said. “And, as far as we can tell, we don’t have a single patient in this program or other program where there’s been any waning of the effect of what we did to the gene or the effect of what we’ve seen with the clinical aspects of the disease itself. So it’s pretty exciting.”

Clarification: This story has been updated to clarify that a patient in a separate trial of a different treatment from Intellia developed acute liver injury and ultimately died from septic shock following an ulcer.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Trending